The pain of acute gout is unbearable
Acute gout is an immune response induced by the rapid change in urate concentration in the joint cavity, which leads to the secretion of inflammatory factors after phagocytosis of urate microcrystals. Generally, the onset is rapid, the pain is unbearable, and the joints and surrounding tissues are affected by redness, swelling, warmth, pain and other symptoms.
At present, the first-line medication of acute gout is Colchicine, NSAID, and COX-2 inhibitor, but these drugs have many toxic and side effects. Due to the high frequency of acute gout in gout patients, long-term medication is required. The toxic and side effects of first-line medications such as colchicine often limit their use in the field of gout. Patients with acute gout would be eager for the emergence of new drugs with equivalent efficacy and low toxicity.
Atom Bioscience's ABP-745 has exhibited higher safety and tolerability advantages than current drugs on the market
ABP-745, developed by Atom Bioscience, has shown significant pharmacodynamic activity in the animal model of acute gout, which can significantly improve the gait, reduce the swelling rate of ankle joints and reduce the level of inflammatory factor. In addition, the nonclinical data showed that ABP-745 exhibited higher safety and tolerability advantages compared with the current therapeutic drugs on the market. Atom Bioscience is actively promoting the research and development process of other indications for ABP-745.